COVID-19パンデミックの間、SARS-CoV-2ウイルスが人間の健康に与える影響に焦点を当てた複数の研究が行われました。マイクロバイオームの配列解析サービスは、COVID-19が人間のマイクロバイオームに与える影響を研究するのに大いに役立ちました。例えば、2021年3月に「フロンティア医学ジャーナル」に掲載された記事では、パンデミックが腸内マイクロバイオームに与える直接的および間接的な影響、およびそれらが研究や臨床試験に与える影響について探求しています。

世界中で癌の症例が増加していることは、マイクロバイオームシーケンシングサービス市場の発展にも寄与しています。たとえば、2022年にオーストラリア癌協会が更新したデータによると、2022年にはオーストラリアで162,163件の新しい癌の症例が診断されると推定され、そのうち88,982件は男性、73,181件は女性であるとされています。この情報源は、オーストラリアでは約5人に2人（すなわち43%）が85歳までに癌と診断されると推定されるとも述べています。年々症例数の大幅な増加は、効率的な治療研究のための癌ゲノミクス研究の増加に主要な要因となっており、それが予測期間中のマイクロバイオームシーケンシングサービス市場の成長を促進することになります。

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場ダイナミクス

  • 4.1 市場概要

  • 4.2 市場の促進要因

  • 4.3 市場の抑制要因

    • 4.3.1 ゲノム解読に関わる倫理的・法的問題

    • 4.3.2 NGSデータ解析のための熟練技術者の不足

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 新規参入の脅威

    • 4.4.2 買い手・消費者の交渉力

    • 4.4.3 サプライヤーの交渉力

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメント別（金額別市場規模 - USD Millions）

  • 5.1 技術別

    • 5.1.1 ライゲーションによる配列決定（SBL）

    • 5.1.2 シーケンシング・バイ・シンセシス(SBS)

    • 5.1.3 ショットガンシーケンス

    • 5.1.4 ターゲット遺伝子配列決定

    • 5.1.5 その他の技術

  • 5.2 用途別

    • 5.2.1 消化器系疾患

    • 5.2.2 感染症

    • 5.2.3 中枢神経系疾患

    • 5.2.4 オンコロジー

    • 5.2.5 その他の用途

  • 5.3 地域別

    • 5.3.1 北米

      • 5.3.1.1 米国
      • 5.3.1.2 カナダ
      • 5.3.1.3 メキシコ

    • 5.3.2 ヨーロッパ

      • 5.3.2.1 ドイツ
      • 5.3.2.2 英国
      • 5.3.2.3 フランス
      • 5.3.2.4 イタリア
      • 5.3.2.5 スペイン
      • 5.3.2.6 その他のヨーロッパ

    • 5.3.3 アジア太平洋

      • 5.3.3.1 中国
      • 5.3.3.2 日本
      • 5.3.3.3 インド
      • 5.3.3.4 オーストラリア
      • 5.3.3.5 韓国
      • 5.3.3.6 その他のアジア太平洋

    • 5.3.4 中東・アフリカ

      • 5.3.4.1 GCC地域
      • 5.3.4.2 南アフリカ
      • 5.3.4.3 その他の中東・アフリカ

    • 5.3.5 南米

      • 5.3.5.1 ブラジル
      • 5.3.5.2 アルゼンチン
      • 5.3.5.3 その他の南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 Baseclear BV

    • 6.1.2 Clinical Microbiomics AS

    • 6.1.3 Merieux Nutrisciences Corporations (Biofortis)

    • 6.1.4 Locus Biosciences (EPIBIOME)

    • 6.1.5 Microbiome Insights Inc

    • 6.1.6 MR DNA

    • 6.1.7 Zymo Research

    • 6.1.8 Rancho Biosciences

    • 6.1.9 Metabiomics

    • 6.1.10 CosmosID

    • 6.1.11 ZIFO

    • 6.1.12 Shanghai Realbio Technology (RBT) Co., Ltd

• 7 市場機会と今後の動向

The Microbiome Sequencing Services Market size is estimated at USD 1.71 billion in 2024, and is expected to reach USD 2.36 billion by 2029, growing at a CAGR of 6.70% during the forecast period (2024-2029).

During the COVID-19 pandemic, several studies were focused on the impact of the SARS-CoV-2 virus on the health of the human population. The microbiome sequencing services have extensively helped in studying the COVID-19 impact on the human microbiome. For instance, an article published in the Journal of Frontiers in Medicine in March 2021 explored the direct and indirect influences of the pandemic on the gut microbiome and how these can affect research and clinical trials.

The study showed an extensive interaction between the gut microbiome and the SARS-CoV-2 virus. The disrupted gut microbiome contributed to the course and severity of COVID-19, as the loss of beneficial microbes, the proliferation of potentially harmful microbes, and the reduction of microbial diversity contributed to the worsening of health. Thus, the increased use of microbiome sequencing services during the COVID-19 pandemic significantly impacted the growth of the market. However, as the pandemic has subsided currently, the usage of microbiome sequencing is stable due to increased focus on research of other diseases. Thus, the studied market is expected to have normal growth during the forecast period of the study.

Major factors that are driving the market growth include huge investment in microbiome research, a rise in demand for NGS services, the surge in genomic research, and the widening application area of microbiome sequencing.

The increasing demand for Next-Generation Sequencing is a major factor attributing to the growth of the microbiome sequencing services market. For instance, an article published in the Journal of Clinical Investigation in April 2022 indicated that Next-generation sequencing (NGS) technology has advanced the understanding of the human microbiome by allowing for the discovery and characterization of unculturable microbes with the prediction of their function. Such innovations in the next-generation sequencing services are expected to boost the growth of the microbiome sequencing services market.

The rise in genomic research all over the world is also contributing to the growth of the microbiome sequencing services market in the forecast period. For instance, according to the National Human Genome Research Institute of the United States National Institute of Health, data on Genomic Data Science updated in April 2022, indicated that as biomedical research projects and large-scale collaborations grow rapidly, the amount of genomic data being generated is also increasing, with roughly 2 to 40 billion gigabytes of data being generated every year. A large number of research and development projects in genomic research are adding to the growth of the microbiome sequencing services market.

Additionally, in June 2021, Illumina and Microba Life Sciences launched a partnership to improve the understanding of the human gut microbiome in human health and diseases. The partnership will combine Illumina's revolutionary NGS tools and Microba's high-quality proprietary gut microbiome analysis platform to produce the accurate metagenomic data required by researchers to fuel discoveries. Such research collaborations are also adding to the growth of the studied market.

Thus, the aforementioned factors, such as the increasing genomic research, innovations in NGS technology, and the rising developments by market players, are expected to boost the market growth. However, ethical and legal issues related to genome sequencing and the lack of skilled technicians for NGS data analysis are hindering the growth of the microbiome sequencing services market in the forecast period.

Microbiome Sequencing Services Market Trends

The Oncology Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Oncology holds a significant market share due to the rising number of cancer cases all over the world, and the increasing cancer genomic research is expected to boost the growth of the microbiome sequencing services market. For instance, according to the data published by the National Institute of Health (NIH) in March 2023, the research spending on cancer genomics in the United States is expected to increase from USD 1,232 million in 2022 to USD 1,300 million in 2023. Thus, the increasing research spending on the microbiome of cancer is boosting the growth of the oncology segment in the microbiome sequencing services market in the forecast period.

The rising number of cancer cases around the world is also adding to the developments in the microbiome sequencing services market. For instance, according to the data updated by Cancer Australia in 2022, it was estimated that 162,163 new cases of cancer would be diagnosed in Australia in 2022, out of which 88,982 would be males and 73,181 females. The source also stated that it was estimated that around 2 in 5 people (or 43%) would be diagnosed with cancer by age 85 in Australia. The large increase in the number of cases over the years is majorly contributing to the increase in cancer genomic research for efficient treatment studies, which in turn will propel the growth of the microbiome sequencing services market in the forecast period.

Moreover, the developments by key players in the market are also expected to enhance the market growth. For instance, in June 2022, Cordlife Group and AMILI signed a strategic partnership to provide a gut microbiome banking service in Singapore and the surrounding region. The gut microbiome data would help in future fecal microbiota transplants (FMT) for diseases such as colorectal cancer.

The research and development by key market players in the segment are also adding to the market growth. For instance, in March 2022, Microbiotica raised USD 67 million for its research on microbiome-based immuno-oncology through phase 1b trials, which are to be started later in the year. Such contributions by the market players are expected to propel market growth.

Thus, the aforementioned factors, such as the rising prevalence of cancer, increasing research spending on cancer genomics, and the rising research and development by key market players, are expected to boost the market growth.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

The rise in the adoption of highly advanced techniques and systems in microbiome sequencing services and the technological advancements made in genomic research studies are expected to boost the growth of the market in the North American region. The high awareness among healthcare personnel of the availability of innovative microbiome sequencing services in the market contributes to the high market growth in the region.

The rising number of cancer cases in the North American region is adding to the growth of the microbiome sequencing services market. For instance, as per the Canada Cancer Society's statistics for 2022, around 233,900 Canadians were expected to be diagnosed with cancer in 2022, out of which 121,100 were men and 112,800 were women. Also, as per the American Cancer Society's data for 2023, around 1.95 million new cases of cancer are expected to be diagnosed in the United States in 2023. Thus, the large population affected by cancer and the increase in the necessity of microbiome sequencing services for the ease of diagnosis and treatment of such diseases is expected to propel the growth of the microbiome sequencing services market in the forecast period.

Moreover, researchers from Rutgers University, United States, in their article published in the Journal of Genome Medicine in February 2021, discussed the use of a guild to identify potentially important functional microbiomes associated with specific health outcomes and disease phenotypes through next-generation sequencing. The article suggested that guild-based analysis may create a paradigm shift towards an ecologically meaningful approach to understanding the relationship between the gut microbiome and human health. The rise in the research studies on the microbiome through the use of sequencing services in the United States is likely to add to the growth of the studied market over the forecast period.

Moreover, the developments by key players in the market are also expected to enhance the market growth. For instance, in May 2021, Viome scored an FDA breakthrough labeling for its cancer-screening, microbiome-sequencing AI platform.

Thus, the increasing necessity for microbiome sequencing services coupled with increasing investment in the health care department is known to propel the growth of the market in this region.

Microbiome Sequencing Services Industry Overview

The microbiome sequencing services market is moderately competitive and consists of a number of major players. The initiatives taken by the market players such as the launch of new services and broader offering is also boosting the growth of the market. Companies like Baseclear BV, Clinical Microbiomics AS, Merieux Nutrisciences Corporations, Microbiome Insights Inc., MR DNA, and Zymo Research Corp., among others, hold substantial shares in the microbiome sequencing services market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Huge Investment in Microbiome Research

    • 4.2.2 Rise in Demand for NGS Services

    • 4.2.3 Surge in Genomic Research and Widening Application Area of Microbiome Sequencing

  • 4.3 Market Restraints

    • 4.3.1 Ethical and Legal Issues Related to Genome Sequencing

    • 4.3.2 Lack of Skilled Technicians for NGS Data Analysis

  • 4.4 Porter's Five Forces Analysis

    • 4.4.1 Threat of New Entrants

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Bargaining Power of Suppliers

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD Millions)

  • 5.1 By Technology

    • 5.1.1 Sequencing by Ligation (SBL)

    • 5.1.2 Sequencing by Synthesis (SBS)

    • 5.1.3 Shotgun Sequencing

    • 5.1.4 Targeted Gene Sequencing

    • 5.1.5 Other Technologies

  • 5.2 By Application

    • 5.2.1 Gastrointestinal Diseases

    • 5.2.2 Infectious Diseases

    • 5.2.3 CNS Diseases

    • 5.2.4 Oncology

    • 5.2.5 Other Applications

  • 5.3 Geography

    • 5.3.1 North America

      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico

    • 5.3.2 Europe

      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe

    • 5.3.3 Asia-Pacific

      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific

    • 5.3.4 Middle East and Africa

      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa

    • 5.3.5 South America

      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 Baseclear BV

    • 6.1.2 Clinical Microbiomics AS

    • 6.1.3 Merieux Nutrisciences Corporations (Biofortis)

    • 6.1.4 Locus Biosciences (EPIBIOME)

    • 6.1.5 Microbiome Insights Inc

    • 6.1.6 MR DNA

    • 6.1.7 Zymo Research

    • 6.1.8 Rancho Biosciences

    • 6.1.9 Metabiomics

    • 6.1.10 CosmosID

    • 6.1.11 ZIFO

    • 6.1.12 Shanghai Realbio Technology (RBT) Co., Ltd

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS